glp-1 autism Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Autism symptoms in adults and

Evidence quality across them varies considerably

Glucagon-like peptide 1 receptor agonist ameliorates the insulin resistance function of islet cells via the activation of PDX-1/JAK signaling transduction in C57/BL6 mice with high-fat diet-induced diabetes

Over the next five years, the marketplace will only grow more crowded: cheaper generics, oral pills replacing injections, and an escalating marketing war as companies expand indications from diabetes and obesity into sleep apnea, fatty liver disease, even addiction

Because GLP-1s are expensive, they drive massive top-line revenue, but the actual gross margins are razor-thin (or negative in some markets due to PBM reimbursements)

No - it remains a research peptide